Accession Number : AD1051151

Title :   Potential Therapeutic Use of Relaxin in Healing Cranial Bone Defects

Descriptive Note : Technical Report,01 Aug 2016,31 Aug 2017

Corporate Author : University of Florida Gainesville United States

Personal Author(s) : Conrad, Kirk P

Full Text :

Report Date : 01 Sep 2017

Pagination or Media Count : 11

Abstract : The overall objective is to provide proof-of-principle that recombinant human relaxin (rhRLX) administration will accelerate bone healing in a calvarial defect model in mice by promoting angiogenesis/vasculogenesis and osteogenesis, at least in part through incorporation of bone marrow-derived angio- and osteogenic progenitor cells into the lesion. Results from the second study conducted during this reporting period demonstrated: reproducible implementation of uniform cranial lesions of 1.5 mm diameter and circulating concentrations of relaxin ranging from 0.35-3.41 ng/ml. However, after 10-12 days of healing, the lesion closure was comparable in the relaxin- and vehicle-treated mice (50 ).

Descriptors :   xray computed tomography , bone marrow , blood vessels , stem cells , bone fractures , osteogenesis , therapy , immunochemistry , stem cells

Subject Categories : Medicine and Medical Research

Distribution Statement : APPROVED FOR PUBLIC RELEASE